Skip to main content

Table 1 Patient Characteristics 1

From: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Characteristics

No. of Patients

%

Total enrolled

11

 

Gender

  

   Female

8

73

   Male

3

27

Age (y)

  

   Median

55

 

   Range

46-70

 

ECOG performance status

  

   1

6

55

   2

0

0

   3

3

27

   4

2

18

Histology

  

   Adenocarcinoma

10

91

   Squamous

1

9

Smoking history

  

   Current

3

27

   Ex-smoker

1

9

   Never

7

64

EGFR mutation

  

   Exon 19 deletion

2

18

   L858R

1

9

   Not available

8

73

  1. EGFR, epidermal growth factor receptor.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us